StocksMedium•9 November 2026•
1 min read
Roivant Sciences Beats Q2 Estimates with Significant Revenue Outperformance
Key Facts
1Roivant Sciences reported a GAAP EPS loss of $0.27, beating analyst estimates by $0.09.
2The company reported revenue of $35.12M, significantly beating estimates by $31.01M.
Roivant Sciences reported a GAAP EPS loss of $0.27 for its fiscal second quarter, beating analyst estimates by $0.09. Investing.com reported that the company generated $35.12M in revenue, significantly outperforming expectations by a margin of $31.01M.
The stock of Roivant Sciences, traded under the ticker ROIV, closed at $38.88 on November 6, 2026. The shares traded between a day low of $36.62 and a high of $39.08 during that session, preceding the financial results that showed the company outperforming consensus estimates on both the top and bottom lines.